Cellgene Bioscience Appears at the 7th BIONNOVA Forum: Focusing on HCP, Facilitating Drug Discovery and Quality Control Monitoring
From April 22nd to 23rd, 2026, the 7th BIONNOVA Biomedical Innovators Forum and Exhibition was grandly held at the Zhangjiang Science and Technology Center in Shanghai. This conference brought together many top experts and scholars, business leaders and technical elites in the field of biomedicine, and focused on in-depth exchanges and discussions on cutting-edge areas such as cell and gene therapy (CGT), antibody drugs, and nucleic acid drugs.
As a leading player in the field of quality inspection for biopharmaceuticals, Cellgene Bioscience showcased its core products and solutions at Booth B22, sharing new opportunities for the development of the CGT industry with global industry colleagues. What is even more remarkable is that the co-founder and technical director of Cellgene Bioscience, Dr. Yan Jizhou, was invited to deliver a keynote speech at the "CGT Production Processes and CMC" sub-forum, sharing the latest breakthrough achievements of Cellgene Bioscience in the quality control of host cell proteins (HCP).
Stunning Display: High Popularity at B22 Booth
At booth B22, Cellgene Bioscience showcased a comprehensive range of products, including the main host cell protein (HCP)/DNA (HCD)/RNA (HCR) residual detection kits, the mycoplasma qPCR detection kit manual (fluorescent probe method), the mycoplasma detection kit (PCR-membrane strip method), as well as other external risk factors such as HSA, BSA, kanamycin, Human PLBL2, etc., in the biopharmaceutical quality control product series.
During the exhibition, the Cellgene booth attracted many pharmaceutical company R&D personnel, quality control experts and industry partners to engage in exchanges on coverage, recovery rate, and linear correlation technology. The company's sales and technical teams conducted in-depth discussions with the visiting guests on these issues and shared Saitang's practical experience and solutions in the field of quality control.
Thought Delight: Dr. Yan Jizhou Shares New Insights on HCP Quality Control
On the afternoon of April 23rd, at the CGT Production Technology and CMC Special Forum, Yan Jizhou, the co-founder and technical director of Cellgene Bioscience, delivered a keynote speech titled "Focusing on HCP, Facilitating Drug Discovery and Quality Control Monitoring".
HCP testing: The "quality gatekeeper" for CGT products
Dr. Yan Jizhou pointed out that in the production of gene therapy and cell therapy products, the residual host cell protein (HCP) is one of the key quality attributes that affect the safety and efficacy of the products. By presenting real data and conducting longitudinal comparisons, it can be discovered which inflammatory responses are caused by excessive HCP residue and the changes in specific inflammatory factor levels in the body.
Another more dangerous "molecule" worthy of attention - residual exogenous nucleic acids
Dr. Yan Jizhou believes that in CGT biological residues, apart from HCP, the residual of exogenous nucleic acids is more obvious. In particular, live vectors (live viruses) and active small nucleic acids are more dangerous.
Cellgene Plan: Empowering the Industrialization Process of CRISPR-Cas Technology
Dr. Yan Jizhou, by combining multiple practical cases, demonstrated the application effectiveness of Cellgene Bioscience's HCP/HCD detection products in the R&D and production of CGT products. The company can provide residual detection kits covering 20 or more host cells such as CHO, 293, E.coli, and Pichia pastoris, as well as dedicated detection solutions for high-risk factors such as PLBL2 and Protein A, providing full-chain support for the safety evaluation and quality control of CGT products.
The speech elicited enthusiastic responses from the attendees, and many of the listeners expressed their willingness to engage in cooperation and exchange.
Deepen quality control and grow together with the industry
The two-day BIONNOVA forum has come to a successful conclusion. Through this exhibition, Saitang Biotechnology not only showcased its technical accumulation and innovation capabilities in the field of drug quality control, but also established deeper communication and cooperation with industry colleagues.
As a professional service provider specializing in biopharmaceutical quality control based in Zhangjiang and serving the global market, Cellgene Bioscience will continue to uphold the core concept of "professional technology, professional service, and professional products". It will focus on cutting-edge fields such as CGT and antibody drugs, continuously improve technical platforms such as host residue detection and process impurity analysis, and provide more precise and reliable quality control solutions to empower the high-quality development of China's biopharmaceutical industry.
